摘要
为观察吉非替尼(Iressa)对初治的晚期非小细胞肺癌(NSCLC)的疗效及毒副反应,选取20例晚期NSCLC患者进入研究,所有患者均未接受过化疗,吉非替尼剂量为250mg/次,口服,1次/d,全组中位服药持续时间为10个月。结果:20例患者均可评价,获得CR2例(10.0%)、PR3例(15.0%)、SD6例(30.0%)、PD9例(45.0%),总的疾病控制率为55.0%;疾病相关症状改善率为75.0%。与药物相关的不良反应依次为:皮疹9例(45.0%),腹泻6例(30.0%),恶心4例(20.0%),皮肤干燥5例(25.0%),未观察到间质性肺炎病例。初步观察结果显示,吉非替尼对晚期NSCLC具有较好的疗效,不良反应轻微,可以考虑作为一些体质较差、不能耐受手术、放疗或化疗的NSCLC患者的一线治疗。
The objective of this study was to observe the curative effect and adverse event of non-small cell lung cancer （NSCLC） patients who received gefitinib（Iressa）. Twenty patients who hadn＇t experienced any regimen of chemotherapy were selected. Gefitinib was given, as a single drug, at a dose of 250 mg per day orally. The median time for administration of gefitinib was 10 months. Among these 20 patients, complete response was 2 （10.0 % ）, partial response 3（15.0%）, stable disease 6（30.0%）, progressive disease 9（45.0%）, symytom improvement 75.0%. The drug-related adverse reactions were skin rash 9 （45.0%）, diarrhea 6 （30. 0%）, nausea 4 （20. 0%）, xerosis curls 5 （25.0%）. No interstitial lung disease was found. In conclusion, gefitinib has good effect on the patients with NSCLC. So gefitinib may be accepted as second or third line drug in the treatment of advanced NSCLC and as first line drug in the treatment of patients with bad constitution who have no opportunities for operation, irradiation therapy or chemotherapy.
出处
《中华肿瘤防治杂志》
CAS
2007年第19期1500-1501,共2页
Chinese Journal of Cancer Prevention and Treatment
